" class="no-js "lang="en-US"> Ola Engkvist - Medtech Alert
Thursday, March 28, 2024
Ola Engkvist

Ola Engkvist

About Ola Engkvist

After I completed my PhD in Computational Chemistry at the University of Lund and postdoctoral research at the University of Cambridge and the Czech Academy of Sciences, I joined AstraZeneca in 2004. I currently lead the Discovery Sciences Computational Chemistry team within BioPharmaceuticals R&D, providing computational solutions for drug discovery.

I am passionate about pushing the boundaries of using artificial intelligence and machine learning in drug discovery. A key focus for me has been on building both the team within BioPharmaceuticals R&D and collaborating with external experts to advance innovation in drug design and synthesis.

Through a pioneering collaboration with the University of Muenster, my team demonstrated the first application of recurrent Neural Networks to molecular design which has been published in two recent, highly-cited articles. This methodology allows us to design novel drug molecules using machine learning to navigate the breadth of chemical space and to exploit our vast knowledge base.

Related Story

Drug Discovery Gets Jolt of AI via NVIDIA Collaborations with AstraZeneca, U of Florida Health

May 21 2021

NVIDIA is collaborating with biopharmaceutical company AstraZeneca and the University of Florida’s academic health center, […]